GSK 2190914

Drug Profile

GSK 2190914

Alternative Names: 2190914; AM103; GSK-2190914

Latest Information Update: 14 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Amira Pharmaceuticals; GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Cardiovascular disorders

Most Recent Events

  • 14 Oct 2014 Discontinued - Phase-I for Cardiovascular disorders in Europe (PO)
  • 14 Oct 2014 Discontinued - Phase-II for Asthma in Europe (PO)
  • 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top